Mike Henney

Overview

Chief Product and Supply Chain Officer at Bicycle Therapeutics, leading the company's entry into radiopharmaceutical manufacturing with lead-212 alpha therapy. Mike Henney is Chief Product and Supply Chain Officer at Bicycle Therapeutics, where he is building robust development and supply chains for a novel radiopharmaceutical modality based on phage display bicyclic peptides. Henney emphasizes that Bicycle Therapeutics' radiopharmaceutical products have a 10-hour half-life, meaning the window from manufacture to patient dosing is under 10 hours — a fundamentally different paradigm from conventional pharmaceuticals that target 3-5 year shelf life. (Segment 1 (00:00-05:00))